COST-EFFECTIVENESS OF PEMBROLIZUMAB PLUS CHEMOTHERAPY, WITH OR WITHOUT BEVACIZUMAB FOR THE FIRST-LINE TREATMENT OF PD-L1-POSITIVE PATIENTS WITH PERSISTENT, RECURRENT, OR METASTATIC CERVICAL CANCER IN FRANCE

被引：0

作者：

Ray-Coquard, I ^{[1
,2
,3
]}

Pautier, P. ^{[4
]}

Muston, D.

Monberg, M. J. ^{[5
]}

Swami, S. ^{[6
]}

Chaker, O. ^{[7
]}

Bensimon, L. ^{[8
]}

Lange, S. ^{[9
]}

Kulakova, M. ^{[10
]}

Zaleski, Durand, I ^{[11
]}

Marie, L. ^{[9
]}

机构：

[1] Ctr Leon Berard, Lyon, France

[2] Univ Claude Bernard Lyon 1, Lyon, France

[3] GINECO, Lyon, France

[4] Inst Gustave Roussy, Villejuif, France

[5] Merck & Co Inc, Rahway, NJ USA

[6] MSD UK Ltd, London, England

[7] MSD, Paris, France

[8] MSD, Puteaux La Defense, Ile De France, France

[9] Steve Consultants, Paris, France

[10] Lumanity, Sheffield, S Yorkshire, England

[11] ECEVE UMR 1123, Creteil, France

来源：

VALUE IN HEALTH | 2023年 / 26卷 / 12期

关键词：

D O I：

暂无

中图分类号：

F [经济];

学科分类号：

02 ;

摘要：

PT33

引用

页码：S201 / S201

页数：1

共 50 条

[1] COST-EFFECTIVENESS OF PEMBROLIZUMAB IN FIRST-LINE TREATMENT OF PD-L1 POSITIVE PERSISTENT, RECURRENT, OR METASTATIC CERVICAL CANCER
Nedzesky, J.
Veenstra, D.
[J]. VALUE IN HEALTH, 2022, 25 (07) : S343 - S343
[2] Cost-effectiveness of pembrolizumab plus chemotherapy as first-line treatment in PD-L1-positive metastatic triple-negative breast cancer
Huang, Min
Fasching, Peter
Haiderali, Amin
Pan, Wilbur
Gray, Emma
Zhou, Zheng-Yi
Hu, Peter
Chaudhuri, Mitashri
De Tilleghem, Celine Le Bailly
Cappoen, Nicolas
O'Shaughnessy, Joyce
[J]. IMMUNOTHERAPY, 2022, 14 (13) : 1027 - 1041
[3] COST-EFFECTIVENESS OF PEMBROLIZUMAB FOR FIRST-LINE TREATMENT IN PATIENTS WITH PERSISTENT, RECURRENT, OR METASTATIC CERVICAL CANCER IN THE UNITED STATES
Monk, Bradley
Boer, Jennifer
Van Hees, Frank
Van Mens, Sophie
Swami, Shilpi
Muston, Dominic
Tekin, Cumhur
Keefe, Steve
Monberg, Matthew
[J]. INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, 2022, 32 : A38 - A38
[4] Comparative cost-effectiveness of first-line pembrolizumab plus chemotherapy vs. chemotherapy alone in persistent, recurrent, or metastatic cervical cancer
Lin, Ying-tao
Wang, Chang
He, Xiao-yan
Yao, Qi-min
Chen, Jian
[J]. FRONTIERS IN IMMUNOLOGY, 2024, 14
[5] COST EFFECTIVENESS ANALYSIS OF PEMBROLIZUMAB AS FIRST-LINE TREATMENT FOR PERSISTENT, RECURRENT, OR METASTATIC CERVICAL CANCER IN GREECE
Yfantopoulos, N.
Gountas, I
Swami, S.
Skroumpelos, A.
Karokis, A.
[J]. VALUE IN HEALTH, 2023, 26 (12) : S62 - S62
[6] COST-EFFECTIVENESS ANALYSIS OF PEMBROLIZUMAB plus CHEMOTHERAPY FOR PERSISTENT, RECURRENT, OR METASTATIC CERVICAL CANCER IN JAPAN
Akai, M.
Moriwaki, K.
Morimoto, K.
Shimozuma, K.
[J]. VALUE IN HEALTH, 2024, 27 (06) : S69 - S69
[7] Pembrolizumab with or without bevacizumab for recurrent or metastatic cervical cancer: A cost-effectiveness analysis
Barrington, David A.
Riedinger, Courtney
Haight, Paulina J.
Tubbs, Crystal
Cohn, David E.
[J]. GYNECOLOGIC ONCOLOGY, 2022, 165 (03) : 500 - 505
[8] Cost-effectiveness of pembrolizumab versus chemotherapy as first-line treatment in PD-L1-positive advanced non-small-cell lung cancer in the USA
Huang, Min
Lopes, Gilberto de Lima
Insinga, Ralph P.
Burke, Thomas
Ejzykowicz, Flavia
Zhang, Ying
Feliciano, Josephine L.
[J]. IMMUNOTHERAPY, 2019, 11 (17) : 1463 - 1478
[9] Cost-effectiveness analysis of pembrolizumab plus chemotherapy with PD-L1 test for the first-line treatment of NSCLC
Wan, Ning
Zhang, Tian-tian
Hua, Si-hua
Lu, Zi-luo
Ji, Bo
Li, Li-xia
Lu, Li-qing
Huang, Wen-jie
Jiang, Jie
Li, Jian
[J]. CANCER MEDICINE, 2020, 9 (05): : 1683 - 1693
[10] Pembrolizumab with chemotherapy, with or without bevacizumab for persistent, recurrent, or metastatic cervical cancer
McNamara, Blair
Chang, Yifan
Mutlu, Levent
Harold, Justin
Santin, Alessandro D.
[J]. EXPERT OPINION ON BIOLOGICAL THERAPY, 2023, 23 (03) : 227 - 233

← 1 2 3 4 5 →